Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish pharmaceutical firm Novo Nordisk has invested about $126m in new diabetes laboratories at its research and development (R&D) campus in Måløv, Denmark.
Subscribe to our email newsletter
Construction has already started and the new Diabetes Research House facility is scheduled to be opened in early 2016.
Following completion, the new Diabetes Research House will be responsible for the research and development of new drugs and will be capable of accommodating about 350 employees.
The company said that during the construction phase, the project will generate more than 1,000 external jobs.
Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: "The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry.
"Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes."
The new three-storey 16,500m² facility will include two laboratory wings, a middle building with office space and an auditorium with capacity for around 450 people.
The company opened its R&D campus in Måløv in 1991 with about 300 employees and now it has more than 2,300 employees.
At the company’s R&D units in Denmark, the US and China, there are about 5,000 employees involved in research and development activities.
Image: Novo Nordisk’s new Diabetes Research House designed to research and develop new drugs will open in early 2016. Photo: courtesy of Novo Nordisk.